Goldman Sachs has begun coverage of Structure Therapeutics, designated by the ticker GPCR, initiating it with an "Early-Stage Biotech" rating. This move reflects the investment bank's assessment of the company's potential within the biotech sector. This initiation could draw increased attention from investors who follow Goldman Sachs' recommendations in the market. The rating signifies confidence in GPCR's capabilities and market opportunities as it progresses in its sector. Investors might watch this stock closely for further developments or updates from analysts.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Structure Therapeutics Inc (GPCR, Financial) is $79.31 with a high estimate of $120.00 and a low estimate of $50.00. The average target implies an upside of 315.22% from the current price of $19.10. More detailed estimate data can be found on the Structure Therapeutics Inc (GPCR) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, Structure Therapeutics Inc's (GPCR, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
